Achieved a score of none or mild and at least a two-grade improvement in BLESS III.
A trusted resource for modern practices
← Aesthetic Injectables
Globally trusted.
LetibotulinumtoxinA-wlbg · 100 units
Globally trusted.
Proven results.
A fresh U.S. advantage.
Letybo® is an FDA-approved neurotoxin made in Korea—and Korea’s #1 best-selling neurotoxin—now giving U.S. practices a compelling new choice.
Known globally as K-Tox
Korean aesthetics,
now in U.S. practices.
Patients are increasingly aware of Korean aesthetics—and many are asking for Letybo by name.
Its international heritage gives practices a story patients recognize, while its focused U.S. launch creates an opportunity to offer something differentiated. ElleVie supports the clinical education, positioning and business planning needed to introduce it thoughtfully.
For the patient conversation
A clear introduction to K-Tox.
The updated patient brochure brings together Letybo’s Korean heritage, approved indication, expected timing, representative results and Important Safety Information in one polished resource your practice can share.
View patient brochureDigital PDF · Updated June 2026
#1Best-selling neurotoxin in Korea
15+Years of clinical experience
44M+Treatments worldwide
70+Countries worldwide
The BLESS clinical program
Reliable outcomes,
supported by evidence.
Letybo was evaluated in three international Phase III studies involving more than 1,200 patients across 31 study centers.
Achieved at least a two-grade improvement at maximum frown at Week 4.
Achieved at least a two-grade improvement at maximum frown at Week 4.
BLESS III subjects with moderate-to-severe glabellar lines received 20 units of Letybo or placebo. Percentages and study descriptions are manufacturer reported; review the current Prescribing Information for complete study design and results.
Patient-centered performance
Designed around the treatment rhythm practices already know.
Visible results
In a Phase III study, 24% of patients reported improvement within 24 hours and 75% reported improvement by Day 3.
A familiar treatment rhythm
Manufacturer patient materials report results lasting up to four months, with patients receiving three treatments per year on average.
Approved glabellar dose
Five injections of 4 units each across the corrugator and procerus muscles, per current prescribing information.
Actual patient
Before, Week 4
and Month 4.
Unretouched representative Letybo results provided by the manufacturer. Photographs were taken at maximum frown. Individual outcomes vary.
An uncomplicated partnership
A product opportunity built for modern practices.
Letybo combines global brand credibility with a practical business model designed to give providers more flexibility and help support healthier treatment margins.
01Portfolio strategyPosition Letybo within your current neuromodulator mix.
02Team educationProduct knowledge, clinical resources and launch readiness.
03Patient positioningIntroduce the K-beauty heritage clearly and responsibly.
04Ongoing supportOrdering guidance, promotions and account follow-through.
Important safety information
For licensed healthcare professionals.
WARNING: DISTANT SPREAD OF TOXIN EFFECT. The effects of all botulinum toxin products, including Letybo, may spread from the area of injection and produce symptoms consistent with botulinum toxin effects. Swallowing and breathing difficulties can be life threatening, and deaths have been reported.
INDICATION. Letybo® (letibotulinumtoxinA-wlbg) is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Do not receive Letybo if you are allergic to any ingredient or botulinum toxin product, or if you have a skin infection at the planned injection site. The most common side effect was headache. Letybo dosing units are not the same as, or comparable to, any other botulinum toxin product.
Review full Prescribing Information and Medication Guide ↗See how Letybo could fit your injectable portfolio.
Talk with ElleVie